Amarin is still in a holding pattern, waiting for an FDA ruling on its key drug Vascepa's NCE status, but that didn't stop Citigroup from initiating coverage with a buy recommendation and a $20 price target that is a near double from where shares sit today. Watch as Motley Fool health-care analyst David Williamson discusses why Citi likes Amarin so much and whether he agrees with that assessment.
David Williamson owns shares of Pfizer and Amarin. Follow him on Twitter, @MotleyDavid. The Motley Fool owns shares of AstraZeneca, Citigroup, and GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
